特一药业
(002728)
| 流通市值：48.33亿 | | | 总市值：49.48亿 |
| 流通股本：5.01亿 | | | 总股本：5.13亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 393,321,980.2 | 209,871,725.36 | 924,529,614.92 | 691,850,596.25 |
| 营业收入 | 393,321,980.2 | 209,871,725.36 | 924,529,614.92 | 691,850,596.25 |
| 二、营业总成本 | 356,299,176.39 | 178,504,163.17 | 851,118,940.49 | 626,752,024.99 |
| 营业成本 | 169,432,699.33 | 81,879,711.36 | 419,507,843.3 | 297,911,088.34 |
| 税金及附加 | 3,676,399.87 | 1,419,072.19 | 13,926,698.71 | 9,097,481.32 |
| 销售费用 | 119,323,166.35 | 65,151,781.9 | 299,220,130.26 | 236,315,696.51 |
| 管理费用 | 41,654,411.41 | 20,116,426.52 | 72,277,603.8 | 51,546,722.82 |
| 研发费用 | 20,298,244.28 | 9,247,883.81 | 44,405,153.73 | 30,217,212.6 |
| 财务费用 | 1,914,255.15 | 689,287.4 | 1,781,510.69 | 1,663,823.41 |
| 其中:利息费用 | 2,011,538.68 | 775,836.8 | 4,232,345.79 | 3,652,835.27 |
| 其中:利息收入 | 314,947.24 | 119,765.17 | 2,779,217.63 | 2,224,092.42 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 2,062,457.52 | 1,398,476.22 | 795,560.28 | 748,710.96 |
| 资产处置收益 | 0 | 0 | -68,451.01 | -59,687.76 |
| 资产减值损失(新) | 0 | - | -1,661,224.29 | - |
| 信用减值损失(新) | 938,933.55 | 1,089,066.22 | 1,967,022.49 | 2,035,396.55 |
| 其他收益 | 3,016,107.41 | 1,759,308.01 | 6,706,459.45 | 5,357,085.46 |
| 四、营业利润 | 43,040,302.29 | 35,614,412.64 | 81,150,041.35 | 73,180,076.47 |
| 加:营业外收入 | 54,885.38 | 5,436.46 | 2,737,624.79 | 2,522,394.41 |
| 减:营业外支出 | 787,000.06 | 484,330.24 | 1,602,794.95 | 869,804.4 |
| 五、利润总额 | 42,308,187.61 | 35,135,518.86 | 82,284,871.19 | 74,832,666.48 |
| 减:所得税费用 | 11,200,071.85 | 9,372,277.14 | 613,255.79 | 9,615,536.69 |
| 六、净利润 | 31,108,115.76 | 25,763,241.72 | 81,671,615.4 | 65,217,129.79 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 31,108,115.76 | 25,763,241.72 | 81,671,615.4 | 65,217,129.79 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 31,108,115.76 | 25,763,241.72 | 81,671,615.4 | 65,217,129.79 |
| 扣除非经常损益后的净利润 | 29,714,397.2 | 24,864,647.81 | 79,578,965.24 | 62,809,651.26 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 0.05 | 0.16 | 0.13 |
| (二)稀释每股收益 | 0.06 | 0.05 | 0.16 | 0.13 |
| 九、综合收益总额 | 31,108,115.76 | 25,763,241.72 | 81,671,615.4 | 65,217,129.79 |
| 归属于母公司股东的综合收益总额 | 31,108,115.76 | 25,763,241.72 | 81,671,615.4 | 65,217,129.79 |
| 公告日期 | 2026-08-21 | 2026-04-28 | 2026-03-24 | 2025-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |